MBOT
Microbot Medical Inc.
Set alert
- YTD
- -45.50%
- 1 year
- -49.54%
- Open
- 1.11
- Prev close
- 1.12
- Mkt cap
- 73.21M
- Vol
- 1.33M
- Avg vol
- 700.77K
- EPS
- -0.25
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.04
- High
- 1.11
- Forward P/E
- -1.87
- Beta
- 1.63
- Short ratio
- 2.65
- Inst. own
- 7.46%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.9736
- 200-d avg
- 1.00
- 1y target
- 0.00
Key statistics
- Market cap
- 16.43M
- Enterprise value
- 9.37M
- Trailing P/E
- 0.00
- Forward P/E
- -1.87
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.53
- EPS (TTM)
- -0.79
- Beta
- 1.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.59M
- Total cash
- 6.46M
- Total debt
- 148.00K
- Return on equity
- -134.46%
- Shares outstanding
- 16.93M
- Short % of float
- 3.51%
- 50-day average
- 0.9736
- 200-day average
- 1.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.17 | -0.20 | -0.03 | -17.65% |
| Aug 14, 2024 | Jun 1, 2024 | -0.17 | -0.17 | 0.00 | 0.00% |
| May 15, 2024 | Mar 1, 2024 | -0.17 | -0.17 | 0.00 | 0.00% |
| Mar 27, 2024 | Dec 1, 2023 | -0.25 | -0.26 | -0.01 | -4.00% |
| Nov 14, 2023 | Sep 1, 2023 | -0.25 | -0.21 | +0.04 | +16.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.31 | -0.25 | +0.06 | +19.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 18, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 6, 2023 | HC Wainwright & Co. | reit | — | Buy |
| May 9, 2023 | HC Wainwright & Co. | main | — | Buy |
About Microbot Medical Inc.
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- microbotmedical.com
News
- Microbot Medical Receives Order From ELMNT IR For 12-Month Supply Of Liberty Devices
- Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
- Citizens Initiates Coverage On Microbot Medical with Market Outperform Rating, Announces Price Target of $2.5
- Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
- HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target
- Microbot Medical Receives Several New Patent Approvals Across US, Japan, China And Canada, Further Strengthening Its Global IP Portfolio
- Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio
- Microbot Medical Inks Three-Year Distribution Deal With Medtechnica To Advertise, Sell LIBERTY System In Israel
- Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
- Microbot Medical® Highlights Growth Strategy
Your note
Sign in to keep a note on MBOT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.71% | 459,549 | 445.81K | Sep 29, 2024 |
| Blackrock Inc. | 0.81% | 137,375 | 133.27K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.78% | 132,217 | 128.26K | Sep 29, 2024 |
| AlphaCentric Advisors LLC | 0.59% | 100,000 | 97.01K | Sep 29, 2024 |
| UBS Group AG | 0.26% | 44,503 | 43.17K | Sep 29, 2024 |
| Hilltop Holdings Inc. | 0.18% | 30,689 | 29.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.06% | 348,549 | 338.13K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.64% | 108,034 | 104.80K | Sep 29, 2024 |
| Mutual Fund Ser Tr-AlphaCentric Robotics & Automation Fund | 0.59% | 100,000 | 97.01K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 80,889 | 78.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 22,796 | 22.11K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 20,503 | 19.89K | Oct 30, 2024 |